Stallergenes Greer announces change of auditor
LONDON--(BUSINESS WIRE)--
Stallergenes Greer (Paris:STAGR), a biopharmaceutical company specialising in treatments for respiratory allergies, announces that following the completion of a formal audit tender process, conducted in accordance with the relevant requirements and led by the Company's Audit Committee, the Board has approved the appointment of EY LLP as the Company's auditor for the financial year commencing 1 January 2017. This appointment was approved by shareholders at the Company’s Annual General Meeting held on 8 June 2017.
The Board of extends its appreciation and thanks to PwC LLP for its past contributions.
ABOUT STALLERGENES GREER PLC
Headquartered in London (UK),
Stallergenes Greer plc is a global healthcare company specialising in
the diagnosis and treatment of allergies through the development and
commercialisation of allergy immunotherapy products and services.
Stallergenes Greer Plc is the parent company of GREER Laboratories, Inc.
(whose registered office is in the US) and Stallergenes SAS (whose
registered office is in France). Additional information is available at http://www.stallergenesgreer.com.
Trading information
Name: Stallergenes Greer
ISIN:
GB00BZ21RF93 1 - Ticker: STAGR
ICB Classification: 4577
Market:
Euronext Paris regulated market
Communications and Investor Relations
Natacha Gassenbach
Tel:
+1 (617) 225 8013
Email: natacha.gassenbach@stallergenesgreer.com
or
Investor
Relations Agency
FTI Consulting
Arnaud de Cheffontaines
Tel:
+33 1 47 03 69 48
Email: arnaud.decheffontaines@fticonsulting.com
or
Media
Bloom
Serra
Saridereli
Tel: +1 (212) 715 1604
Email: Sariderelis@bloompr.com
or
Havas
Worldwide Paris
Samuel Rousseau
Tel: +33 (0) 6 51 03 51 43
Email:
samuel.rousseau@havas.com
DISCLAIMER
This document (including information incorporated
by reference in this document), oral statements made and other
information published by the Company contain statements that are or may
be forward-looking with respect to the financial condition and/or
results of operations and businesses of the Company. These statements
can be identified by the use of forward-looking terminology such as
"believe," "expects," "project," "estimated," "forecast," "should,"
"plan," "may" or the negative of any of these, or other variations
thereof, or comparable terminology indicating expectations or beliefs
concerning future events. These forward-looking statements include risk
and uncertainty because they relate to events and depend on
circumstances that will occur in the future. Without being exhaustive,
such factors include economic situations and business conditions,
including legal and product evaluation issues, fluctuations in
currencies and demand, and changes in competitive factors. These and
other factors are more fully described in the Company's 2016 annual
report published on 28 April 2017 on the Company's website www.stallergenesgreer.com.
Actual results may differ from those set forth in the forward-looking
statements, due to various factors. Save as required by applicable law,
neither the Company nor any other person assumes any obligation to
update these forward-looking statements or to notify any person of any
such update.